Compare Regeneron Pharmaceuticals Inc (REGN) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Suncor Energy Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Suncor Energy Inc. trades at $64.78 (market cap $75.38B). The key difference: Regeneron Pharmaceuticals Inc and Suncor Energy Inc. are close in size by market cap, and Suncor Energy Inc. pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| REGN | SU | |
|---|---|---|
Market Cap | $70.79B | $75.38B |
Sector | Health | Energy |
52-Week High | $812.27 | $69.73 |
52-Week Low | $545.46 | $38.17 |
Enterprise Value | $64.74B | $83.58B |
Dividend Yield | 0.56% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Suncor Energy (SU) trades at $63.70, up 2.03% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but beat in the prior two quarters. Valuation ratios appear reasonable with a P/E of 16.8 and EV/EBITDA of 7.08. Strong profitability is evident with a net income margin of 11.62% and ROE of 13.97%. A dividend of $0.60 per share is scheduled for payment on June 25, 2026.
The outlook for SU is supported by record production and integrated operations, but faces risks from oil price volatility and operational incidents. Analyst consensus is strongly bullish with 74% buy ratings. The stock's performance hinges on upcoming Q2 2026 results and broader energy market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
